Clinical Trials Browser

Phase 3 × Nasopharyngeal Neoplasms × Radiotherapy, Intensity-Modulated × Clear all

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT05587374 2025-01-23

GEMSTONE

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms